Search clinical trials for: Meningococcal meningitis

Total 717 results

Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
Wei Cun
Yunnan Center for Disease Control and Prevention

Unknown

A Phase III Clinical Trial of the Group A and C Meningococcal Polysaccharide Vaccine

Meningitis, Meningococcal

China
St George's, University of London
GlaxoSmithKline; Public Health England; MeningitisNow

Completed

Babies Born Early Antibody Response to Men B Vaccination: BEAR Men B (BEAR Men B)

Prematurity | Meningococcal Disease | Vaccination

United Kingdom
University Hospital, Montpellier

Unknown

Evaluation of Post Infectious Inflammatory Reaction (PIIR) Concerning Children After Streptococcus Pneumoniae, Streptococcus Pyogenes and Neisseria Meningococcus Invasive Infection (RIPI)

Streptococcus Pyogenes Infection | Streptococcus Pneumonia | Neisseria Meningitides Meningitis

France
Public Health England

Completed

Comparison of Two Meningococcal ACWY Conjugate Vaccines (PRIME)

Meningococcal Meningitis

United Kingdom
GlaxoSmithKline
Novartis Vaccines

Completed

Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.

Meningococcal Disease | Infections, Meningococcal

Taiwan
Novartis Vaccines

Completed

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Invasive Meningococcal Disease

United States, Poland
University of Southampton
University Hospital Southampton NHS Foundation Trust

Completed

Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA) (NadA-Lac4)

Meningitis, Bacterial | Neisseria Infection

United Kingdom
GlaxoSmithKline

Completed

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

Meningitis, Meningococcal

Czechia
Walvax Biotechnology Co., Ltd.

Completed

Safety Evaluation of Meningococcal Group ACYW135 Conjugate Vaccine in 2-month to 55 Years Old Population.

Meningococcal Infections

China
Belfast Health and Social Care Trust
Queen's University, Belfast; Royal College of Emergency Medicine; Pediatric Emergency... and other collaborators

Completed

Petechiae In Children (PIC) Study: Defining A Clinical Decision Rule for The Management Of Fever and Non-Blanching Rashes In Children Including The Role Of Point Of Care Testing For Procalcitonin & Neisseria Meningitidis DNA. (PIC)

Sepsis | Meningitis, Meningococcal | Meningitis | Meningococcal Infections | Meningococcal Disease | Meningococcal Sepsis

United Kingdom
GlaxoSmithKline

Completed

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Infections, Meningococcal

United States, Puerto Rico
GlaxoSmithKline

Completed

Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents

Infections, Meningococcal

Finland, Poland
Epicentre
Medecins Sans Frontieres, Netherlands

Withdrawn

Ciprofloxacin for the Prevention of Meningococcal Meningitis 2018

Meningitis, Meningococcal

Niger
University Hospital Southampton NHS Foundation...
University of Southampton

Unknown

A Study Assessing Colonisation & Immunogenicity After Nasal Inoculation With N. Lactamica and Eradication on Day 4 or 14 (Lac-3)

Meningitis, Meningococcal

United Kingdom
GlaxoSmithKline

Completed

The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers

Infections, Meningococcal

United States
St George's, University of London

Unknown

Evaluation of Safety and Immunogenicity of Meningococcal B and Meningococcal ACWY Vaccine in at Risk Population (ProPositive)

HIV Infections | Hiv | Meningitis, Meningococcal

United Kingdom
Public Health England

Completed

Pertussis and Meningitis C Concomitant Vaccination in Adolescents (Mutliboost)

Pertussis | Meningitis | Immunization | Preventive Immunization; Meningitis

United Kingdom
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
GlaxoSmithKline

Completed

Combined Study - Phase 3b MenB Long Term Persistence in Adolescents

Infections, Meningococcal

Chile, Canada, Australia
U.S. Army Medical Research and Development Command
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety and Immunogenicity Study of Group B Meningococcal Vaccine to Prevent Meningitis.

Meningitis, Meningococcal, Serogroup B

United States
The Immunobiological Technology Institute (Bio-Manguinhos)...

Unknown

Conjugate Vaccine Against Meningococcus C a Brazilian Project

Serogroup C Meningococcal Meningitis

Brazil
Novartis Vaccines

Completed

Safety and Immunogenicity of Meningococcal ACWY Conjugate Versus Polysaccharide Vaccine in Children 2 to 10 Years of Age

Meningococcal Disease

Argentina
Novartis Vaccines

Completed

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Meningococcal Disease | Meningococcal Meningitis

United States, Canada
Novartis
Novartis Vaccines

Completed

Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Subjects From 2 to 75 Years of Age in India

Bacterial Meningitis

India
Novartis Vaccines

Completed

Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

Meningococcal Meningitis

Canada
Prof. Elizabeth Miller
Novartis Vaccines

Completed

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults (MenOccy)

Meningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup W

United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

Meningococcal Disease

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants

Infections, Meningococcal

Mexico, Argentina
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults

Infections, Meningococcal

Thailand, Estonia, Dominican Republic
Merck Sharp & Dohme LLC

Completed

RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)

Meningitis, Meningococcal | Rotavirus Infections
Novartis Vaccines

Completed

Persistence Of Antibody Responses Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine or Meningococcal C Conjugate Vaccine

Meningococcal Disease

Germany
Novartis Vaccines

Completed

Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10

Meningococcal Disease | Meningococcal Meningitis

Chile
Epicentre
Medecins Sans Frontieres, Netherlands

Completed

Ciprofloxacin for the Prevention of Meningococcal Meningitis

Meningitis, Meningococcal

Niger
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers

Meningitis | Meningococcal Infection

Australia
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Novartis Vaccines
GlaxoSmithKline

Completed

Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants

Serogroup B Meningococcal Meningitis

Austria, Czechia, Finland, Germany, Italy
Novartis Vaccines
GlaxoSmithKline

Completed

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12

Meningococcal Disease | Meningococcal Meningitis

Belgium, Czechia, Germany, Italy, Spain, United Kingdom
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Persistence of Antibody Response to N. Meningitidis Group C in Children

Prevention of Meningococcal Infection

Spain, Poland
Novartis Vaccines
GlaxoSmithKline

Completed

Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Meningococcal Meningitis

United States
Novartis Vaccines
GlaxoSmithKline

Completed

Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine

Hepatitis B | Hepatitis A | Meningococcal Disease | Meningococcal Meningitis

Germany
Novartis
Novartis Vaccines

Completed

Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers

Meningococcal Disease | Meningococcal Meningitis

Poland
Public Health England

Withdrawn

Host-pathogen Interactions in Meningococcal Disease: Finding the Key That Fits the Lock (Lock and Key)

Meningitis

United Kingdom
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Novartis Meningococcal B Vaccine When Administered to Immunocompromised Children and Adolescents Compared to Healthy Subjects.

Meningococcal Disease

Italy, Poland, Russian Federation, Spain, United Kingdom
Novartis Vaccines

Completed

Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents

Meningococcal Disease

United States
University of Oxford

Completed

Understanding the Immune Response to Two Different Meningitis Vaccines

Meningitis | Meningococcal Disease | Septicaemia

United Kingdom

3

Subscribe